Secondary acute myeloid leukaemia (sAML) arising from prior myeloid neoplasia or after anticancer therapy accounts for ~25% of AML cases and has a poor prognosis. Nevertheless, the ‘7 + 3’ cytarabine and daunorubicin regimen has remained the standard induction therapy for >40 years. Now, the improved efficacy of a nanoparticle formulation of cytarabine and daunorubicin, CPX-351, in older patients (aged 60–75 years) with sAML — who have particularly dismal outcomes with 7 + 3 therapy — has been confirmed in a phase III trial.
CPX-351 consists of cytarabine and daunorubicin encapsulated in liposomes at a 5:1 synergistic molar ratio. The phase III trial of this agent was conducted to validate an overall survival (OS) benefit for older patients with newly diagnosed sAML observed in a prior randomized phase II trial. In the phase III trial, the median OS duration in the CPX-351 group (n = 153) was 9.6 months versus 6.0 months in the 7 + 3 group (n = 156; HR 0.69; 95% CI 0.52–0.90; P = 0.003); estimated 2-year OS was 31.1% versus 12.3%. Correspondingly, patients in the CPX-351 group were more likely to achieve remission (47.7% versus 33.3%) and to undergo allogeneic haematopoietic stem cell transplantation (34% versus 25%), with the results of an exploratory analysis of survival after transplantation favouring CPX-351 (HR 0.46, 95% CI 0.24–0.89; P = 0.009). Subgroup analyses suggested fairly consistent OS benefits across most subgroups, although prior exposure to hypomethylating agents seemed to reduce the likelihood of benefit from CPX-351.
In agreement with the prolonged plasma circulation and drug exposure of CPX-351, neutrophil and platelet recovery times were delayed relative to those observed with the 7 + 3 regimen. Nevertheless, the overall safety profiles of the two treatments were similar.
In August 2017, CPX-351 became the first FDA-approved treatment for sAML on the basis of these data.
References
Original article
Lancet, J. E. et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J. Clin. Oncol. https://doi.org/10.1200/JCO.2017.77.6112 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. Benefit of nanomedicine confirmed in sAML. Nat Rev Clin Oncol 15, 591 (2018). https://doi.org/10.1038/s41571-018-0080-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0080-5